trending Market Intelligence /marketintelligence/en/news-insights/trending/rhPU4gu8e5ScL6Y1nldCsA2 content esgSubNav
In This List

Kee Song Bio-Technology Q3 profit climbs YOY


Gold - Geopolitical tensions and inflation remain key drivers


Lithium and Cobalt - Softer demand weighs on prices


Street Talk | Episode 94: Recessionary fears in ’22 overblown, Fed could overtighten


Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Kee Song Bio-Technology Q3 profit climbs YOY

Kee Song Bio-Technology Holdings Ltd said its normalized net income for the third quarter was NT$1.01 per share, compared with the S&P Capital IQ consensus estimate of NT$1.10 per share.

EPS climbed year over year from 40 cents.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was NT$35.5 million, a gain from NT$13.6 million in the prior-year period.

The normalized profit margin climbed to 6.4% from 4.1% in the year-earlier period.

Total revenue grew 68.7% year over year to NT$558.1 million from NT$330.7 million, and total operating expenses grew 58.2% year over year to NT$493.0 million from NT$311.7 million.

Reported net income rose from the prior-year period to NT$45.2 million, or NT$1.29 per share, from NT$16.0 million, or 47 cents per share.

As of Nov. 16, US$1 was equivalent to NT$32.83.